Payment overview · 2025
General Payments
$124.40
1 reported records · 1 companies
Healthcare provider profile · identity verified
Samuel Warren Ralston, MD
Allopathic & Osteopathic Physicians|Family Medicine · WACO, TX · NPI 1891767539
Verified facts
What the public records show
CMS Open Payments records show Samuel Warren Ralston, MD received $124.40 in general payments during 2025 across 1 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $124.40 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.40 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $124.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 683 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 520 | 121 |
| Hydrochlorothiazide | Hydrochlorothiazide | 381 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 354 | 85 |
| Gabapentin | Gabapentin | 344 | 79 |
| Losartan Potassium | Losartan Potassium | 339 | 79 |
| Lisinopril | Lisinopril | 292 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 63 |
| Sertraline Hcl | Sertraline Hcl | 181 | 44 |
| Metformin Hcl Er | Metformin Hcl | 179 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 33 |
| Alprazolam | Alprazolam | 175 | 40 |
| Metformin Hcl | Metformin Hcl | 167 | 42 |
| Simvastatin | Simvastatin | 167 | 46 |
| Omeprazole | Omeprazole | 153 | 39 |
| Alendronate Sodium | Alendronate Sodium | 147 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 32 |
| Bupropion Xl | Bupropion Hcl | 128 | 29 |
| Ozempic | Semaglutide | 125 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 31 |
| Valsartan | Valsartan | 114 | 27 |
| Tramadol Hcl | Tramadol Hcl | 113 | 34 |
| Potassium Chloride | Potassium Chloride | 109 | 25 |
| Celecoxib | Celecoxib | 107 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 23 |
| Allopurinol | Allopurinol | 102 | 26 |
| Carvedilol | Carvedilol | 99 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 20 |
| Montelukast Sodium | Montelukast Sodium | 94 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 94 | 23 |
| Meloxicam | Meloxicam | 89 | 20 |
| Clonazepam | Clonazepam | 86 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 17 |
| Trazodone Hcl | Trazodone Hcl | 84 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 71 | 18 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 71 | suppressed |
| Glimepiride | Glimepiride | 69 | 20 |
| Eliquis | Apixaban | 66 | 12 |
| Ezetimibe | Ezetimibe | 65 | 15 |
| Furosemide | Furosemide | 63 | 23 |
| Lovastatin | Lovastatin | 63 | 17 |
| Donepezil Hcl | Donepezil Hcl | 55 | 13 |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 12 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 11 |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Prednisone | Prednisone | 34 | 24 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 11 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | 12 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.40 · 1 records | Kowa Pharmaceuticals America, Inc. | ZORYVE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error